Trials / Completed
CompletedNCT03289533
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
AN OPEN LABEL, SINGLE ARM PHASE 1B STUDY OF AVELUMAB PLUS AXITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab (MSB0010718C) | Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID. |
| DRUG | Axitinib (AG-013736) | Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID. |
Timeline
- Start date
- 2017-09-08
- Primary completion
- 2019-08-27
- Completion
- 2019-10-25
- First posted
- 2017-09-21
- Last updated
- 2020-09-04
- Results posted
- 2020-09-04
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03289533. Inclusion in this directory is not an endorsement.